CRISPR Therapeutics AG CRSP
NASDAQ CRSP
$50.50 +0.62 (+1.24%)
At close: Oct 21, 2026 · 4:00 PM EDT

CRISPR Therapeutics AG (CRSP) Preferred Stock Liabilities (2015 - 2016)

Updated

CRISPR Therapeutics AG (CRSP) reported Preferred Stock Liabilities of $185.57 million for Q3 2016.

Analysis

CRISPR Therapeutics AG (CRSP) Preferred Stock Liabilities (2015 - 2016) Analysis & Trends

At the end of FY2015, CRISPR Therapeutics AG posted Preferred Stock Liabilities of $64.52 million, up 929.0% from FY2014.

  • By year, Preferred Stock Liabilities came in at $6.27 million in FY2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 CRISPR Therapeutics AG 4.88 Bn -3.82 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2016 185.57 Mn
Dec 31, 2015 64.52 Mn
API Access

CRISPR Therapeutics AG Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=CRSP&period=max&api_key=YOUR_API_KEY